These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7333702)

  • 1. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients.
    Godolphin W; Elwood JM; Spinelli JJ
    Int J Cancer; 1981 Dec; 28(6):677-83. PubMed ID: 7333702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival with breast cancer: the importance of estrogen receptor quantity.
    Shek LL; Godolphin W
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):243-50. PubMed ID: 2702979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptors in primary breast cancer.
    Neifeld JP; Lawrence W; Brown PW; Banks WL; Terz JJ
    Arch Surg; 1982 Jun; 117(6):753-7. PubMed ID: 7082164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis.
    Shek LL; Godolphin W
    Cancer Res; 1988 Oct; 48(19):5565-9. PubMed ID: 3416309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval.
    Lippman ME; Allegra JC
    Cancer; 1980 Dec; 46(12 Suppl):2829-34. PubMed ID: 7448729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer.
    Skinner JR; Wanebo HJ; Betsill WL; Wilhelm MC; Drake CR; Macleod RM
    Ann Surg; 1982 Dec; 196(6):636-41. PubMed ID: 7149814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis].
    Chevallier B; Heintzman F; Asselain B; Dauce JP; Bastit P; Graic Y; Brunelle P; Basuyau JP; Comoz M
    Bull Cancer; 1988; 75(1):23-36. PubMed ID: 3359056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor level and other factors in early recurrence of breast cancer.
    Westerberg H; Gustafson SA; Nordenskjöld B; Silfverswärd C; Wallgren A
    Int J Cancer; 1980 Oct; 26(4):429-33. PubMed ID: 7251221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients.
    Shek LL; Godolphin W; Spinelli JJ
    Br J Cancer; 1987 Dec; 56(6):825-9. PubMed ID: 3435707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
    Crowe JP; Gordon NH; Hubay CA; Shenk RR; Zollinger RM; Brumberg DJ; McGuire WL; Shuck JM
    Surg Gynecol Obstet; 1991 Oct; 173(4):273-8. PubMed ID: 1925896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
    Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
    J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases.
    Maki HS; Hoehn JL
    Arch Surg; 1989 Mar; 124(3):377-80. PubMed ID: 2919970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading.
    Parl FF; Schmidt BP; Dupont WD; Wagner RK
    Cancer; 1984 Nov; 54(10):2237-42. PubMed ID: 6488142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.
    Kiba T; Inamoto T; Nishimura T; Ueno M; Yanagihara K; Teramukai S; Kato H; Toi M; Fukushima M
    BMC Cancer; 2008 Nov; 8():323. PubMed ID: 18990247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
    Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
    Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
    Meyer JS; Province MA
    Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer.
    Paridaens R; Sylvester RJ; Ferrazzi E; Legros N; Leclercq G; Heuson JC
    Cancer; 1980 Dec; 46(12 Suppl):2889-95. PubMed ID: 7448734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.